CyberKnife Therapy Prevents Prostate Cancer in Men at Low to Intermediate Risk, Study Says

CyberKnife Therapy Prevents Prostate Cancer in Men at Low to Intermediate Risk, Study Says
Men at low risk of prostate cancer who got radiation therapy with Accuray‘s CyberKnife System were still disease-free after seven years, as were 88.5 percent of men at intermediate risk, concluded a clinical trial by the medical device manufacturer. At seven years after treatment, disease-free survival rates were 100 percent for patients with low-risk of prostate cancer and 88.5

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Chris O'Neill says:

    “disease-free after seven years”

    This study shows nothing about the end-point that men care about, overall survival, which is always unaffected by low, intermediate or even high risk prostate cancer detected after seven years of PSA screening anyway. The same applies to prostate cancer-specific survival so this study is only of academic interest.

Leave a Comment

Your email address will not be published. Required fields are marked *